文献速递心力衰竭与心肌病

SGLT2抑制剂对肾小管钠水氯稳态的影响及其在心衰结局中作用的批判性分析

Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
PubMed 文献 · Circulation · 2023-07-24

本文综述SGLT2抑制剂对肾小管钠、水、氯稳态的影响及其与心衰结局的关系。现有研究显示,该类药物单用或联用利尿剂均无显著急性或慢性利尿/利钠效应,因肾脏代偿迅速且近乎完全;但长期治疗中葡萄糖尿和锂排泄分数持续存在,提示近端小管药理耐受不明显。这种持续近端小管效应可能改善容量稳态的设定点,并与药物对心肌细胞的直接保护作用协同介导心衰获益。

要点

  • SGLT2抑制剂不引起显著急性或慢性利尿/利钠,肾脏代偿迅速且近乎完全。
  • 长期治疗中葡萄糖尿和锂排泄分数持续存在,提示近端小管药理耐受不明显。
  • 持续近端小管效应可能改善容量设定点,并与心肌直接保护作用协同。

核心结论

  • SGLT2抑制剂对肾小管钠水氯稳态的影响有限,但持续近端小管效应可能改善容量设定点并与心肌直接保护作用协同减少心衰事件。

研究设计与样本

  • 综述与综合分析现有研究,评估SGLT2抑制剂对肾小管钠、水、氯稳态的影响及心衰结局。

主要发现

  • SGLT2抑制剂单用或联用其他利尿剂均无显著急性或慢性利尿或利钠效应。
  • 肾脏对SGLT2抑制剂的代偿在数天至数周内迅速且近乎完全,防止进行性容量丢失。
  • 长期治疗中葡萄糖尿和锂排泄分数持续存在,提示近端小管药理耐受不明显。

关键数值与推荐

  • 葡萄糖尿和锂排泄分数在长期SGLT2抑制剂治疗中持续存在,作为近端小管效应持续的指标。

临床怎么用

  • 临床使用SGLT2抑制剂时不应期望显著利尿/利钠效应,其心衰获益可能源于近端小管持续效应与心肌直接保护作用的协同。
  • 容量扩张时SGLT2抑制剂可能通过改善容量设定点发挥临床益处。

局限性

  • 难以确定治疗相关的容量设定点改变是否实际发生或贡献于心衰事件风险降低。
  • 肾脏反应模式在不同研究和临床设置间存在显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose and sodium in the early proximal renal tubule, but the magnitude and duration of any ensuing natriuretic or diuretic effect are the result of an interplay between the degree of upregulation of SGLT2 and sodium-hydrogen exchanger 3, the extent to which downstream compensatory tubular mechanisms are activated, and (potentially) the volume set point in individual patients. A comprehensive review and synthesis of available studies reveals several renal response patterns with substantial variation across studies and clinical settings. However, the common observation is an absence of a large acute or chronic diuresis or natriuresis with these agents, either when given alone or combined with other diuretics. This limited response results from the fact that renal compensation to these drugs is rapid and nearly complete within a few days or weeks, preventing progressive volume losses. Nevertheless, the finding that fractional excretion of glucose and lithium (the latter being a marker of proximal sodium reabsorption) persists during long-term treatment with SGLT2 inhibitors indicates that pharmacological tolerance to the effects of these drugs at the level of the proximal tubule does not meaningfully occur. This persistent proximal tubular effect of SGLT2 inhibitors can be hypothesized to produce a durable improvement in the internal set point for volume homeostasis, which may become clinically important during times of fluid expansion. However, it is difficult to know whether a treatment-related change in the volume set point actually occurs or contributes to the effect of these drugs to reduce the risk of major heart failure events. SGLT2 inhibitors exert cardioprotective effects by a direct effect on cardiomyocytes that is independent of the presence of or binding to SGLT2 or the actions of these drugs on the proximal renal tubule. Nevertheless, changes in the volume set point mediated by SGLT2 inhibitors might potentially act cooperatively with the direct favorable molecular and cellular effects of these drugs on cardiomyocytes to mediate their benefits on the development and clinical course of heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer, Wilcox, Testani, et al. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes. Circulation. 2023. PMID: 37486998. doi:10.1161/CIRCULATIONAHA.123.064346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。